|Jennifer Jean McCann||President of Orphazyme US, Inc.||N/A||N/A||N/A|
Orphazyme A/S does not have significant operations. Previously, the company was engaged in the development of therapies for the treatment of neurodegenerative rare diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Orphazyme A/S’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.